Induced Changes in Ventilatory Responsiveness and Altitude Exposure

This study has been completed.
Sponsor:
Information provided by:
United States Army Research Institute of Environmental Medicine
ClinicalTrials.gov Identifier:
NCT01241513
First received: November 12, 2010
Last updated: July 28, 2011
Last verified: July 2011

November 12, 2010
July 28, 2011
November 2010
May 2011   (final data collection date for primary outcome measure)
Resting Ventilation [ Time Frame: Multiple occasions at sea level and altitude ] [ Designated as safety issue: No ]
A computer-controlled, breath-by-breath gas analyzer and data acquisition system (Vmax 229 Sensormedics Inc, Yorba Linda, CA, or equivalent) will be used for all resting ventilation measures. Volunteers will be awake, fasting, and rested for at least 1.5 h.
Same as current
Complete list of historical versions of study NCT01241513 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Induced Changes in Ventilatory Responsiveness and Altitude Exposure
Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization

The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In this study, the FDA-approved form of ACCY will be used "off-label" (meaning in a way not approved by the FDA).

This study is being conducted by researchers from the United States Army Research Institute of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber located in the basement of USARIEM. A total of approximately 30 volunteers (men and women, military and civilians) will take part in the study. They can expect to be in the study for a minimum of a few hours each day for two weeks.

The investigators hypothesize that ACCY will improve ventilation and oxygenation while at altitude.

This study will determine if modulating reduction/oxidation (redox) status through a temporary increase in the blood ratio of reduced-to-oxidized glutathione (i.e., GSH/GSSG) will increase carotid body chemosensitivity and thus increase ventilation and arterial oxygen saturation (SaO2) during 32 hours of hypobaric hypoxia exposure to 3500 m (11,500 feet). To that end, the study will use an FDA-approved oral suspension form of acetylcysteine (ACCY) to modulate blood redox status under controlled conditions in the Hypobaric Chamber Facility at the USARIEM. Up to 30 healthy, active-duty military personnel or civilians from the local area will be recruited. Two independent treatment groups (placebo and ACCY; up to 15 in each group) will be assessed at sea level and altitude using a between-group experimental design. The two groups will be matched as closely as possible by age, ventilation, fitness, and gender prior to treatment assignment. Neither the staff nor the volunteers will know the treatment received by the groups until the study is completed. Included will be only those men and women who: are 18 to 39 years old, were born at altitudes below 2100 m (7000 feet), are not taking medications that interfere with oxygen delivery and transport (includes sedatives, sleeping aids, tranquilizers and any medication that depresses ventilation, diuretics, alpha and beta blockers); and have no evidence of any physical, mental, and/or medical conditions that would make the proposed study relatively more hazardous. All volunteers will participate over the two-week long study period in multiple standardized assessments that include resting (e.g., resting ventilation, SaO2, questionnaires), sleeping (e.g., heart rate, SaO2) and exercise (e.g., steady-state and time-trial performance, SaO2) measurements. The potential risks to test volunteers include the risks associated with hypobaric hypoxia exposure (e.g., acute mountain sickness [AMS; headache, nausea, insomnia]) and those associated with exercise (e.g., acute musculoskeletal strains and sprains, blisters). The investigators are not aware of any studies reporting problems during oral administration of ACCY in the doses or duration to be used in the present study. There are no direct benefits to the volunteers, except the knowledge of how well they performed at altitude and on the tests in which they participated. If the use of ACCY proves effective at altitude, then soldiers deployed to altitude in the future may have a means to beneficially increase ventilation and SaO2 in a manner similar to that experienced during natural altitude acclimatization.

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Basic Science
  • Altitude
  • Hypoxia
  • Ventilation
  • Oxygen Saturation
Drug: N Acetyl-Cysteine
4 days, 800 mg q.i.d. Oral
Other Name: Acetylcysteine, Solution, USP, 20%, Lot# 1847277
Placebo Comparator: Sea Level and Altitude
Intervention: Drug: N Acetyl-Cysteine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

-

Exclusion Criteria:

  • Volunteers with the following criteria will be EXCLUDED from participation:

Less than 18 years of age Greater than 39 years of age Born at altitudes greater than 2134 m (7000 ft) Living in areas that are more than 1220 m (4,000 feet), or have traveled to areas that are more than 1220 m for more than a few days within the last 2 months.

Abnormal [Hb]/Hct levels or presence of hemoglobin S Known allergies to sulfonamide derivatives Smokers who smoke more than 5 cigarettes per day Tobacco chewers If military, unable to pass the 2-mi run portion of the Army Physical Fitness Test, or equivalent If civilian, not currently running or exercising for at least 20 min/day, 3X/week in "aerobic" activities (e.g., running, biking. swimming, basketball, etc) If they do not want to walk or run multiple times for 1 to 3 hours on a treadmill Unable to meet the U.S. Army height/weight standards Not willing to sleep in bunk beds in a small room (8 feet by 8 feet) with 1 to 3 other volunteers (male and/or female) for 3 nights. If they are claustrophobic Women who are pregnant or planning to conceive during the study period Women who are not willing to take urine pregnancy tests Not willing to drink an eight ounce solution of diet soda that may contain ACCY up to three times per day and then not willing to suck on a peppermint mint right after drinking the solution.

Taking medications that interfere with oxygen delivery and transport (Includes sedatives, sleeping aids, tranquilizers and any medication that depresses ventilation, diuretics, alpha and beta blockers) Evidence of any physical, mental, and/or medical conditions that would make the proposed studies relatively more hazardous. Evidence of prior HAPE or HACE diagnosis Evidence of apnea or other sleeping disorders Evidence of asthma If applicable, unwilling to stop taking all supplements for the two weeks of participation If applicable, all medications (prescription or over-the-counter) must be approved by the PI, and/or the OMSO.

Both
18 Years to 39 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01241513
H10-13
Yes
Charles S. Fulco, Sc.D. Research Physiologist, United States Army Research Institute of Environmental Medicine
United States Army Research Institute of Environmental Medicine
Not Provided
Principal Investigator: Charles S Fulco, ScD United States Army Research Institute of Environmental Medicine
United States Army Research Institute of Environmental Medicine
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP